
|Videos|September 29, 2022
Dr. Joyce on financial toxicity and advanced prostate cancer treatments
Author(s)Urology Times staff
“We really need to be thoughtful about how our treatment recommendations may induce financial toxicity in patients with advanced prostate cancer,” says Daniel D. Joyce, MD.
Advertisement
In this video, Daniel D. Joyce, MD, discusses the take-home message from the recent Journal of Urology study, “Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients,” for which he served as a study author. Joyce is a urologic oncology fellow at Mayo Clinic, Rochester, Minnesota.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA provides guidance on development pathway for testosterone therapy for women
2
Treatment Selection in Advanced Prostate Cancer
3
Annual ACS NCDB report details national trends in prostate cancer care
4
Advice for the Next Generation of Urologists in mCSPC Management
5






